Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081250 · ClinicalTrials.gov registry record · Phase 3
Creatine in Treating Patients With Cancer-Associated Weight Loss
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00081250 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 300 participants.
The verdict
NCT00081250, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
RATIONALE: It is not yet known whether the supplement creatine is effective in increasing weight and improving appetite and quality of life in patients who have cancer. PURPOSE: This randomized phase III trial is studying how well creatine works in increasing weight and improving appetite and quality of life in patients with weight loss caused by cancer.
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT creatine monohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-12 |
| Est. Completion | 2017-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00081250
The ClinicalTrials.gov registry entry for NCT00081250 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00081250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00081250 about?
NCT00081250 is a clinical study titled "Creatine in Treating Patients With Cancer-Associated Weight Loss". RATIONALE: It is not yet known whether the supplement creatine is effective in increasing weight and improving appetite and quality of life in patients who have cancer. PURPOSE: This randomized phase III trial is studying how well creatine works in increasing weight and improving appetite and quali...
What is the current status of trial NCT00081250?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2004-12. Estimated completion is 2017-07.
What interventions are being tested in trial NCT00081250?
The interventions under investigation include: placebo (OTHER), creatine monohydrate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00081250?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.